Tessari Eben 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Oct 16, 2025
Insider Transaction Report
Form 4
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
- Sale
Class A Ordinary Share
2025-10-14$37.65/sh−11,815$444,835→ 29,237 total - Sale
Class A Ordinary Share
2025-10-14$37.99/sh−553$21,008→ 28,684 total - Exercise/Conversion
Share Option
2025-10-14−6,500→ 12,500 totalExercise: $8.83Exp: 2029-09-16→ Class A Ordinary Share (6,500 underlying) - Exercise/Conversion
Class A Ordinary Share
2025-10-14$8.83/sh+6,500$57,395→ 41,052 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.98 and $37.97. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.98 and $38.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F4]The option is fully vested and exercisable.